Keyphrases
17D Vaccine
16%
4-fold
8%
Amino Acid Residues
8%
Attenuated Strain
8%
Between-day
8%
Brain Lesions
8%
Cellular Immunity
8%
Cerebrospinal Fluid
8%
ChimeraX
50%
Dose-response
100%
E Protein
8%
Encephalitis
16%
Envelope Gene
8%
Fold Increase
8%
Genome Sequencing
8%
Homologous Vaccine
8%
Human Vaccines
16%
Humoral Immunity
8%
Illness
8%
Immune Response
8%
Immunogenicity
8%
Japanese Encephalitis Virus
100%
Lesion Score
8%
Lethal Dose
8%
Live Attenuated
8%
Low-level Viremia
8%
Lung Cells
8%
Monkey
50%
Neurovirulence
8%
Neutralizing Antibodies
33%
Pathological Lesions
8%
Preclinical Efficacy
8%
Preclinical Safety
8%
Protective Efficacy
8%
Recombinant Virus
8%
Response Effectiveness
100%
Response to Vaccination
8%
Rhesus
8%
Rhesus Monkey
100%
SA14-14-2
16%
Safety Testing
100%
Sham
8%
Spinal Cord
8%
Standardized Tests
8%
Structural Proteins
8%
Subcutaneous Route
8%
Vaccine Dose
100%
Vaccine Strain
8%
Viremia
25%
Virus
8%
Virus Strains
8%
Virus Vaccine
100%
Wild Strain
8%
Yellow Fever
100%
Immunology and Microbiology
Adoptive Immunity
9%
Antibody Response
9%
Antibody Titer
9%
Cerebrospinal Fluid
9%
Dose Response
100%
Encephalitis
18%
Env (Gene)
9%
Haplorhini
54%
Humoral Immunity
9%
Immune Response
9%
Immunogenicity
9%
Immunology
9%
Japanese Encephalitis Vaccine
100%
Japanese Encephalitis Virus
100%
Japanese Encephalitis Virus Group
100%
Neutralizing Antibody
36%
Recombinant Virus
9%
Rhesus Monkey
100%
Spinal Cord
9%
Type Strain
9%
Viremia
36%
Virus Strain
9%
Wild Type
27%
Yellow Fever
18%
Yellow Fever Virus
100%